PubMed COVID-19 Clinical Care

Various nonpharmaceutical interventions (NPIs) were implemented to alleviate the COVID-19 pandemic since its outbreak. The transmission dynamics of other respiratory infectious diseases, such as seasonal influenza, were also affected by these

CONCLUSIONS: The findings of this meta-analysis indicate that reparixin, an anti-inflammatory drug, improved survival in critically ill or transplant patients (including both COVID-19 and non-COVID-19 patients) without increasing the risk of

Viral particles bind to receptors through multivalent protein interactions. Such high avidity interactions on sensor surfaces are less studied. In this work, three polyelectrolytes that can form biosensing surfaces with different interfacial

People tend to participate in musical activities-whether it is making or listening to music-for reasons that are related to basic psychological needs. This study explored whether the coronavirus pandemic (Covid-19) has changed the reasons for

The aim of this study was to determine the relationship between depression, hopelessness and life satisfaction with death anxiety and the determinants of death anxiety in individuals who have had COVID-19. This descriptive and correlational study was

Viral diseases are the most notorious infective agent(s) causing morbidity and mortality in every nook and corner for ages; viruses are active in host cells, and specific anti-virus medicines' developments remain uncanny. In this century of the

No abstract

The adoption of digital technology by nurses accelerated during the coronavirus disease 2019 (COVID-19) pandemic. However, not all nurses were familiar with the various digital systems used in their organisations and there were reports of digital

A 30-year-old woman visited the dermatology and venereology clinic with red rashes on her cheeks with spreading wounds to the ears present for 6 months. Similar ailments were also found on the chest and upper arms accompanying black spots on both

CONCLUSIONS: The study was terminated prematurely after enrollment of 32% of planned accrual because of recruitment challenges and lower-than-expected event rate. Rivaroxaban prescribed for 35 days in nonhospitalized patients with symptomatic COVID